adverse events

You have access
Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
TAKAE OKUNO, MASAFUMI HONGOH, RYOSUKE TANINO, TAMIO OKIMOTO, YUKARI TSUBATA and TAKESHI ISOBE

Anticancer Research June 2025, 45 (6) 2551-2561; DOI: https://doi.org/10.21873/anticanres.17627
You have access
Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study
LETICIA IGLESIAS, ROCÍO VÍLCHEZ, SANTIAGO AGUÍN, RAMÓN GARCÍA, CAROLINA PENA, ALBERTO CARRAL, GERARDO HUIDOBRO, AUREA MOLINA, JESÚS GARCÍA GÓMEZ, MARTA COVELA, MARINHA COSTA and ANA MEDINA

Anticancer Research March 2025, 45 (3) 1181-1191; DOI: https://doi.org/10.21873/anticanres.17505
Open Access
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
MICHELE DIONESE, DAVIDE BIMBATTI, FRANCESCO PIERANTONI, ELEONORA LAI, ELISA ERBETTA, NICOLÒ CAVASIN, SALIM JUBRAN, UMBERTO BASSO and MARCO MARUZZO

Anticancer Research October 2024, 44 (10) 4379-4386; DOI: https://doi.org/10.21873/anticanres.17267
You have access
Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER
KIRI ENDO, HIROYUKI TANAKA, HAJIME MATSUO, TOSHIHISA ONODA, AYAKA IIDA and TOSHIHIRO ISHII

Anticancer Research June 2024, 44 (6) 2653-2660; DOI: https://doi.org/10.21873/anticanres.17072
You have access
Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma
TAKAHITO SUGASE, TAKASHI KANEMURA, TOMOHIRA TAKEOKA, NORIHIRO MATSUURA, YASUNORI MASUIKE, NAOKI SHINNO, HISASHI HARA, MASATOSHI KITAKAZE, MASAHIKO KUBO, YOSUKE MUKAI, TOSHINORI SUEDA, SHINICHIRO HASEGAWA, HIROFUMI AKITA, JUNICHI NISHIMURA, HIROSHI WADA, MASAYOSHI YASUI, TAKESHI OMORI and HIROSHI MIYATA

Anticancer Research January 2024, 44 (1) 185-193; DOI: https://doi.org/10.21873/anticanres.16801
You have access
Improvement of Medication Guidance Sheet for Total Body Irradiation/Cyclophosphamide Followed by Allogeneic Hematopoietic Stem Cell Transplantation Based on Real Monitoring Data
MAYAKO UCHIDA, SHIGERU ISHIDA, ERIKA MOCHIZUKI, NANA OZAWA, HIROKO YONEMITSU, HIDEKI OCHIAI, HANAE NAKAMURA, TAKEHIRO KAWASHIRI, KOJI KATO, NOBUAKI EGASHIRA, KOICHI AKASHI and ICHIRO IEIRI

Anticancer Research September 2023, 43 (9) 4067-4075; DOI: https://doi.org/10.21873/anticanres.16596
You have access
Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy
MAYAKO UCHIDA, SHIGERU ISHIDA, ERIKA MOCHIZUKI, NANA OZAWA, HIROKO YONEMITSU, HIDEKI OCHIAI, HANAE NAKAMURA, TAKEHIRO KAWASHIRI, KOJI KATO, NOBUAKI EGASHIRA, KOICHI AKASHI and ICHIRO IEIRI

Anticancer Research July 2023, 43 (7) 3321-3329; DOI: https://doi.org/10.21873/anticanres.16508
Open Access
Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment
SATOSHI FUKUDA, YUSUKE NIISATO, MIKI TSUJI, SOMA FUKUDA, YUYA HAGIWARA, TSUBASA ONODA, HIROSUMI SUZUKI, YOSHITAKA TANGE, TAKESHI YAMADA, YOSHIYUKI YAMAMOTO and TOSHIKAZU MORIWAKI

Anticancer Research May 2023, 43 (5) 2085-2090; DOI: https://doi.org/10.21873/anticanres.16369
You have access
Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study
SOICHI TAKEDA, TADASHI NAMISAKI, YUKI TSUJI, YUKI FUJIMOTO, KOJI MURATA, MASAHIDE ENOMOTO, YUKIHISA FUJINAGA, NORIHISA NISHIMURA, KOH KITAGAWA, HIROAKI TAKAYA, KOSUKE KAJI, TAKASHI INOUE, HIDETO KAWARATANI, TAKEMI AKAHANE, AKIRA MITORO and HITOSHI YOSHIJI

Anticancer Research November 2022, 42 (11) 5465-5473; DOI: https://doi.org/10.21873/anticanres.16051
You have access
Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib
YUKI FUJIMOTO, TADASHI NAMISAKI, SOICHI TAKEDA, KOJI MURATA, MASAHIDE ENOMOTO, HIROAKI TAKAYA, YUKI TSUJI, YUKIHISA FUJINAGA, YASUHIKO SAWADA, NORIHISA NISHIMURA, KOH KITAGAWA, KOSUKE KAJI, TAKASHI INOUE, HIDETO KAWARATANI, KEI MORIYA, TAKEMI AKAHANE, AKIRA MITORO and HITOSHI YOSHIJI

Anticancer Research October 2022, 42 (10) 4895-4905; DOI: https://doi.org/10.21873/anticanres.15995

Main menu

User menu

Search

adverse events

Pages